Related Experiment Video
Updated: Aug 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Cholesterol crystal embolism during treatment with low-molecular-weight heparin]
X Belenfant1, C d'Auzac, J Bariéty
1Service de Néphrologie, Hôpital Broussais, Paris.
Insights
Cholesterol crystal embolism can occur during low-molecular-weight heparin treatment. Discontinue this anticoagulant in high-risk patients to prevent severe multi-organ complications.
Area of Science:
- Vascular Medicine
- Nephrology
- Dermatology
Background:
- Cholesterol crystal embolism (CCE) is a known complication of atherosclerotic disease, particularly involving the aorta.
- It can be iatrogenic, often occurring after procedures or treatments that disrupt atherosclerotic plaques.
Observation:
- Two cases of CCE were documented in patients receiving low-molecular-weight heparin (LMWH).
- Both patients presented with multi-organ involvement, including acute renal failure, pulmonary edema, skin necrosis, and gastrointestinal ischemia.
Findings:
- CCE during prophylactic LMWH treatment is a newly reported phenomenon.
- Successful management involved LMWH discontinuation, supportive care, hemodialysis, and corticosteroids.
Implications:
- LMWH should be avoided in patients with diagnosed CCE due to the risk of severe, multi-organ embolic events.
- This finding extends the known risks associated with anticoagulation and interventions in patients with advanced atherosclerosis.
Background:
Cholesterol crystal embolism is often an iatrogenic complication in ulcerated atherosclerosis of the aorta.
Case Reports:
Two cases of multi-organ embolism of cholesterol crystals were histologically proven in patients treated with low-molecular-weight heparin. Both patients had acute renal failure, hypertension with acute pulmonary edema, skin necrosis and ischemia of the digestive tract. Outcome was favorable after discontinuing anticoagulants, symptomatic treatment, definitive hemodialysis and low-dose corticosteroids.
Discussion:
These two cases are the first reported in the literature of cholesterol crystal embolism occurring during prophylactic treatment with low-molecular-weight heparin. They demonstrate that there is a risk of severe cholesterol embolism in high-risk patients after administration of low-molecular-weight heparin as for non-fractionated heparin, fibrinolytics, arteriography and cardiovascular surgery. Low-molecular-weight heparin thus should not be used in patients with a diagnosis of cholesterol crystal embolism.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Cholecystitis

